Dose‐escalated biologic therapy improves outcomes in people with inflammatory bowel disease
Internal Medicine Journal · 28.07.2026
DOI: 10.1111/imj.70562 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, online erschienen am 28.07.2026. Verfasst von Wai Kin Su und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Liverpool Hospital, Liverpool, New South Wales, Australia. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Background
Biologic therapies are effective in inflammatory bowel disease (IBD), yet many people do not achieve adequate or sustained response to standard dosing, which necessitates dose escalation (DE).
Aim
To examine the need for DE and subsequent outcomes in a large real‐world cohort.
Methods
Crohn's colitis care (CCCare) is an electronic medical record used in Australasia. Data flow into a de‐identified clinical quality registry (CQR), which was interrogated in November 2024. DE was defined as maintenance dosing exceeding the standard average daily dose. We examined data before and over 12 months following DE.
Results
Of 6093 courses of biologic therapy, 37.3% ( n = 2272) were DE therapy. Most were for Crohn's disease ( n = 4208, 69.1%); median time from initiating therapy to DE was 5 months (IQR: 0–19), and 74.2% ( n = 1685) remained on DE therapy beyond 12 months. Twelve months post DE, significant increases in remission rates were seen as assessed by faecal calprotectin
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Liverpool Hospital, Liverpool, New South Wales, Australia.
- Crohn's Colitis Cure, Sydney, Australia.
- Gastroenterology and Liver, The Ingham Institute for Applied Medical Research, Liverpool, Australia.
- Department of Anaesthesia, Lyell McEwin Hospital, Adelaide, Australia.
- Medicine and Health (South Western Sydney Clinical School), University of New South Wales, Sydney, Australia.
- Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, Australia.
ORCID-Profile: Wai Kin Su, Susan J Connor, Jane M Andrews
Zitieren
APA
Su, W. K., Wilson, W., Connor, S. J., & Andrews, J. M. (2026). Dose‐escalated biologic therapy improves outcomes in people with inflammatory bowel disease. Internal Medicine Journal. https://doi.org/10.1111/imj.70562
Vancouver
Su WK, Wilson W, Connor SJ, Andrews JM. Dose‐escalated biologic therapy improves outcomes in people with inflammatory bowel disease. Internal Medicine Journal. 2026. doi:10.1111/imj.70562
BibTeX
@article{Su2026,
author = {Su, Wai Kin and Wilson, William and Connor, Susan J and Andrews, Jane M},
title = {Dose‐escalated biologic therapy improves outcomes in people with inflammatory bowel disease},
journal = {Internal Medicine Journal},
year = {2026},
doi = {10.1111/imj.70562}
}
EUVIMED